Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients have?
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients has 166 citations in the OpenAlex counts ScholarIQ stores.
When was Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients published?
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients has 2004 year in the ScholarIQ index.
What is the open-access status of Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients?
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients has hybrid oa status in the ScholarIQ index.
What is the DOI of Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients?
The DOI for Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients is on the source record.
What is the PMID of Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients?
The PMID for Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients is on the source record.
What is the OpenAlex record for Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients?
The OpenAlex for Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients is on the source record.